AR124244A1 - JAK INHIBITOR WITH AN ANALOG OF VITAMIN D FOR THE TREATMENT OF SKIN DISEASES - Google Patents
JAK INHIBITOR WITH AN ANALOG OF VITAMIN D FOR THE TREATMENT OF SKIN DISEASESInfo
- Publication number
- AR124244A1 AR124244A1 ARP210103366A ARP210103366A AR124244A1 AR 124244 A1 AR124244 A1 AR 124244A1 AR P210103366 A ARP210103366 A AR P210103366A AR P210103366 A ARP210103366 A AR P210103366A AR 124244 A1 AR124244 A1 AR 124244A1
- Authority
- AR
- Argentina
- Prior art keywords
- vitamin
- pharmaceutically acceptable
- acceptable salt
- jak inhibitor
- skin diseases
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se refiere al tratamiento tópico de enfermedades de la piel, tales como psoriasis, dermatitis atópica, alopecia, vitíligo, síndrome de Reiter, pitiriasis rubra pilaris, epidermólisis ampollosa simple, queratodermia palmoplantar, paquioniquia congénita, esteatocistoma múltiple, liquen plano cutáneo, linfoma cutáneo de linfocitos T, hidradenitis supurativa, dermatitis de contacto, ictiosis y un trastorno de queratinización, a través de (a) un inhibidor de JAK o una sal farmacéuticamente aceptable de este y (b) vitamina D3, un análogo de la vitamina D3 o una sal farmacéuticamente aceptable de esta. Reivindicación 1: Una formulación farmacéutica para el tratamiento tópico de una enfermedad de la piel, que comprende (a) un inhibidor de JAK o una sal farmacéuticamente aceptable de este y (b) vitamina D3, un análogo de la vitamina D3 o una sal farmacéuticamente aceptable de esta.The present description refers to the topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, multiple steatocystoma, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a keratinization disorder, via (a) a JAK inhibitor or a pharmaceutically acceptable salt thereof and (b) vitamin D3, a vitamin D3 analogue or a pharmaceutically acceptable salt thereof. Claim 1: A pharmaceutical formulation for the topical treatment of a skin disease, comprising (a) a JAK inhibitor or a pharmaceutically acceptable salt thereof and (b) vitamin D3, a vitamin D3 analogue or a pharmaceutically acceptable salt. acceptable of this
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121531P | 2020-12-04 | 2020-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124244A1 true AR124244A1 (en) | 2023-03-01 |
Family
ID=86317666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103366A AR124244A1 (en) | 2020-12-04 | 2021-12-03 | JAK INHIBITOR WITH AN ANALOG OF VITAMIN D FOR THE TREATMENT OF SKIN DISEASES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR124244A1 (en) |
-
2021
- 2021-12-03 AR ARP210103366A patent/AR124244A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001603A1 (en) | Jak inhibitors with a vitamin d analogue for the treatment of skin diseases. | |
| CL2021000881A1 (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin. (application divisional 201802814 | |
| BRPI0514144A (en) | pharmaceutical delivery device | |
| ES2129013B1 (en) | USE OF VITAMIN C OR ITS DERIVATIVES OR ANALOGS TO STIMULATE THE SYNTHESIS OF ELASTIN CUTANEOUS. | |
| Gubanova et al. | 12-month effects of stabilized hyaluronic acid gel compared with saline for rejuvenation of aging hands | |
| WO2017182885A3 (en) | Compositions for the treatment of hyperkeratosis disorders | |
| MXPA06014514A (en) | Topical compositions and methods for epithelial-related conditions. | |
| AR054249A1 (en) | TREATMENT OF SKIN CONNECTIVE TISSUE DISEASES | |
| BR112015005339A8 (en) | use of miracle fruit seed oil as an active ingredient | |
| ECSP10010352A (en) | QUITOSANE GEL FOR DERMATOLOGICAL APPLICATIONS, PROCESS FOR OBTAINING AND USING THE SAME | |
| NZ594618A (en) | Transdermal pharmaceutical preparations | |
| MX2021010058A (en) | Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders. | |
| JP2015521632A5 (en) | ||
| Elelaimy et al. | Genotoxicity of anticancer drug Azathioprine (Imuran): role of Omega-3 (?-3) oil as protective agent | |
| BR0207738A (en) | Highly flexible transdermal therapeutic system with nicotine as active substance | |
| AR047005A1 (en) | INCLUSION BODIES THAT TRANSPORT GLICEROL-PHOSPHATE ACCEPTABLE FOR PHARMACEUTICAL USE | |
| AR124244A1 (en) | JAK INHIBITOR WITH AN ANALOG OF VITAMIN D FOR THE TREATMENT OF SKIN DISEASES | |
| AR084197A1 (en) | COMPOSITION FOR TOPICAL USE FOR THE TREATMENT OF SKIN DISORDERS | |
| ES2628707T3 (en) | Enhanced Topical Composition | |
| AR054361A1 (en) | USE OF PROPENOUS METOXIDIFENIL ADAMANTIL ACID FOR THE TREATMENT OF DERMATOLOGICAL DISEASES | |
| CO2022009437A2 (en) | Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl ]-4,4-dimethylpent-2-enenitrile | |
| KR20240082385A (en) | Whitening composition and method of use | |
| MX2010009578A (en) | Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound. | |
| AR042476A1 (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE A CALCITRIOL ASSOCIATION AND A CLOBETASOL PROPIONATE | |
| MX2024006773A (en) | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases. |